TOKYO, Dec. 09, 2024 — MEDIROM Healthcare Technologies Inc. (NASDAQ: MRM) (“MEDIROM”) reports that its subsidiary, MEDIROM MOTHER Labs Inc., has received orders exceeding 25,000 MOTHER Bracelet units. This includes orders from Japanese firms such as NFES Technologies Inc.
Kouji Eguchi, CEO of MEDIROM, stated, “Our vision is for the MOTHER Bracelet to revolutionize the healthcare technology and wellness sectors. These 25,000+ orders surpass previous totals and demonstrate strong market penetration. The significant orders from NFES Technologies and two other Tokyo Stock Exchange-listed companies validate our technology’s commercial viability.”
About MEDIROM Healthcare Technologies Inc.
MEDIROM, a comprehensive healthcare company, operates over 300 wellness centers in Japan, primarily under its flagship brand Re.Ra.Ku®, and offers various healthcare services. MEDIROM expanded into health technology in 2015, launching “Lav®,” an on-demand training app. In 2020, MEDIROM entered the device market with the “MOTHER Bracelet®” smart tracker. The company launched REMONY, a remote monitoring system for corporate clients in 2023, securing orders across sectors including nursing care, transportation, construction, and manufacturing. MEDIROM aims to leverage its diverse offerings to gather and manage healthcare data, establishing itself as a leader in healthcare big data. For details, visit https://medirom.co.jp/en.
Contact:
Investor Relations Team
E-mail:
No Offer or Solicitation
This press release and its contents do not constitute an offer to sell or a solicitation of an offer to buy securities in the U.S. or elsewhere, and no securities will be offered or sold where prohibited.
Forward-Looking Statements Regarding MEDIROM
This press release includes forward-looking statements under the U.S. Private Securities Litigation Reform Act of 1995. These statements, which may use terms like “may,” “will,” “should,” “expect,” “plan,” “anticipate,” or similar expressions, relate to MEDIROM’s potential operational results, financial position, strategies, market opportunities, competitive standing, industry context, and growth prospects. These statements involve risks and uncertainties that could significantly affect MEDIROM’s actual results. Therefore, you should not over-rely on forward-looking statements.
- MEDIROM’s ability to meet its business development goals and implement its growth strategies;
- Changes in Japanese and global economic conditions and financial markets impacting MEDIROM’s expansion;
- MEDIROM’s ability to achieve and maintain profitability in its Digital Preventative Healthcare Segment;
- Fluctuations in foreign exchange rates affecting MEDIROM’s expenses and foreign currency liabilities;
- MEDIROM’s ability to protect its brands and intellectual property;
- MEDIROM’s ability to secure additional capital;
- MEDIROM’s level of debt and related restrictions;
- Changes in consumer preferences and the competitive landscape;
- MEDIROM’s ability to manage natural disasters and pandemics; and
- The regulatory environment affecting MEDIROM’s operations.
More details on these and other risks are in MEDIROM’s SEC filings, including the “Risk Factors” and “Operating and Financial Review and Prospects” sections of its Form 20-F and subsequent filings (available at www.sec.gov). MEDIROM is not obligated to update forward-looking statements.
